064 证券代码：300233 证券简称：金城医药 公告编号：2023- 山东金城医药集团股份有限公司 关于子公司注射用头孢哌酮钠通过仿制药 质量和疗效一致性评价的公告 IMS 数据显示头孢哌酮钠主要在中国、越南、印度尼西亚等国家上市销 售，头孢哌酮钠中国市场销售占比超 70%，通用名注射用头孢哌酮钠占比近 30%。米内网数据显示，2020 年~2023 年全国城市公立医院销售额分别为 6627 万人民币、3545 万人民币、3293 万人民币。目前国内包括我司在内仅有 5 家企 业通过仿制药质量和疗效一致性评价，分别为山东润泽制药有限公司、苏州东 瑞制药有限公司、南京赛瑞谱顿制药有限公司、南京恩泰医药科技有限公司、 广东金城金素制药有限公司。 三、对公司的影响及风险提示 本次金城金素注射用头孢哌酮钠 0.5g、1.0g、2.0g 通过仿制药质量和疗效 一致性评价，有利于扩大该产品的市场销售，提高市场竞争力。由于药品销售受 国家政策、市场环境等不确定因素的影响，敬请广大投资者注意风险，理性投资。 特此公告。 山东金城医药集团股份有限公司董事会 2023 年 8 月 17 日 | 本公司及董事会全体成员保证信息 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300233 证券简称：金城医药 公告编号：2023-063 山东金城医药集团股份有限公司 关于独立董事取得独立董事资格证书的公告 2023 年 8 月 15 日 山东金城医药集团股份有限公司（以下简称"公司"）于 2023 年 4 月 21 日召开 2022 年年度股东大会，审议通过了《关于董事会换届选举及提名第六届 董事会独立董事候选人的议案》，同意选举李福利先生为公司第六届董事会独立 董事，任期自 2022 年年度股东大会审议通过之日起至第六届董事会届满之日止。 截至 2022 年年度股东大会决议公告披露日，李福利先生尚未取得独立董事 资格证书，其承诺将参加最近一次独立董事培训并取得深圳证券交易所认可的独 立董事资格证书。 公司董事会于 2023 年 8 月 15 日收到李福利先生通知，其已按照相关规定 参加了深圳证券交易所举办的上市公司独立董事任前培训，并取得了由深圳证券 交易所创业企业培训中心颁发的《上市公司独立董事资格证书》特此公告。 山东金城医药集团股份有限公司董事会 ...

Financial Performance - Net profit for the current period was 54,879,668.97, down from 116,066,574.08, representing a decline of approximately 52.73%[2] - Total comprehensive income attributable to the parent company decreased from 112,478,901.17 to 55,665,887.71, a decline of about 50.5%[2] - Net profit attributable to shareholders for Q1 2023 was ¥50,154,655, down 55.41% from ¥112,478,901 in the previous year[22] - The net profit attributable to the parent company decreased by 55.41% to ¥50,154,655.33 compared to ¥112,478,901.17 in the previous period, primarily due to a decline in the newly added intermediate CMO business[29] Earnings and Shares - Basic earnings per share decreased from 0.29 to 0.13, a drop of about 55.17%[2] - The basic earnings per share for Q1 2023 was ¥0.13, down 55.17% from ¥0.29 in the same period last year[22] Cash Flow - Cash inflow from operating activities increased from 661,072,899.99 to 772,155,286.99, an increase of approximately 16.79%[3] - The total cash flow from operating activities included 10,001,603.09 received from tax refunds, up from 7,508,060.50 in the previous period[3] - Net cash flow from operating activities improved to ¥26,703,337, compared to a negative cash flow of ¥45,797,444 in Q1 2022, representing a 158.31% increase[22] - The net cash flow from operating activities increased by 158.31% to ¥26,703,337.29, compared to a negative cash flow of ¥45,797,444.13 in the previous period, mainly due to an increase in sales collections[30] Assets and Liabilities - Total liabilities decreased slightly from 2,166,771,533.90 to 2,159,237,199.88, a reduction of approximately 0.57%[1] - Total assets at the end of Q1 2023 were ¥5,887,219,350.40, reflecting a 1.05% increase from ¥5,826,083,590.97 at the end of the previous year[22] - The company's equity attributable to shareholders increased by 1.77% to ¥3,671,272,645.90 from ¥3,607,438,065.73[22] - The total assets of the company reached CNY 5,887,219,350.40, up from CNY 5,826,083,590.97, reflecting a growth of about 1.06%[36] - The company's total liabilities were reported at CNY 2,790,796.70 for current liabilities, a decrease from CNY 3,760,327.97, indicating a reduction of about 25.73%[36] Expenses - Research and development expenses decreased from 43,235,054.66 to 28,502,407.61, a reduction of about 34.06%[8] - Sales expenses increased from 130,277,440.43 to 150,312,138.72, an increase of approximately 15.4%[8] - The total financial expenses rose by 88.64% to ¥7,965,178.08, attributed to an increase in exchange losses during the reporting period[29] Investments - The company's long-term equity investments increased by 32.12% to ¥19,556,722.62, resulting from increased external investments by subsidiaries during the reporting period[29] - The company's long-term equity investments rose to CNY 19,556,722.62 from CNY 14,802,516.67, an increase of approximately 32.5%[36] Cash and Equivalents - Cash and cash equivalents at the end of Q1 2023 totaled ¥825,415,392.71, up from ¥805,876,092.95 at the end of the previous year[22] - The company experienced a net increase in cash and cash equivalents of ¥35,635,968.30, contrasting with a decrease of -¥77,971,249.67 in Q1 2022[22] - Cash and cash equivalents reached CNY 926,336,241.84, up from CNY 859,028,154.40, indicating an increase of about 7.83%[34] Current Assets - The total current assets at the end of the period amounted to CNY 2,341,669,250.86, an increase from CNY 2,308,149,145.99 at the beginning of the year, reflecting a growth of approximately 1.45%[34] - Accounts receivable decreased slightly to CNY 575,924,203.06 from CNY 580,559,523.88, a decline of approximately 0.11%[34] - Inventory levels were reported at CNY 576,607,625.20, down from CNY 579,217,125.83, representing a decrease of about 0.45%[36] Other Financial Metrics - The company's tax payable decreased by 37.86% to ¥34,459,814.77, mainly due to a reduction in payable VAT and corporate income tax[29] - The company's special reserves increased significantly by 293.15% to ¥3,743,883.46, attributed to an increase in special reserve provisions during the reporting period[29]

证券代码：300233 证券简称：金城医药 山东金城医药集团股份有限公司 投资者关系活动记录表 编号：2023-001 答:感谢投资者提问！2023年公司主要在4AA系列产品 、 烟碱以及制剂端的国家集采中标产品等方面会有显著增长。 具体数据关注公司定期报告。 8.公司应收账款按账龄统计1至2年有5,066,737.49元 2 至3年有113,128.43元3至4年有3,697,256.90元4至5年有 14,663,204.86元5年以上有34,262,682.12元 为什么2至3年 的应收账款明显少于其它账龄的？上述应收账款中有多少金 额已经逾期？请具体说明欠款对象、金额和逾期原因？公司 采取了哪些追讨措施？上述欠款对象目前经营情况如何？ 答:（1）公司2-3年超期应收款金额较小，主要是公司积 极加强应收款管理，减少超期应收账款金额。（2）上述应收 款中1年以上金额为逾期金额。（3）主要逾期对象详见公司 按单项计提应收账款坏账明细。（4）公司通过安排专人催收 及采用法律手段等多种方式积极催收超期货款。（5）上述应 收款公司已按会计准则计提相应减值准备。 9.贵司的市值管理有无具体的规划？ 答:尊敬的投资者 ...

一、会议召开的时间、地点和方式 证券代码：300233 证券简称：金城医药 公告编号：2023-041 山东金城医药集团股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为 便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 04 月 10 日（星期一）15:00-17:00 在"价值在线"（www.ir-online.cn） 举行山东金城医药集团股份有限公司 2022 年度业绩说明会，与投资者进行沟通 和交流，广泛听取投资者的意见和建议。 会议召开时间：2023 年 04 月 10 日（星期一）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 出席本次网上业绩说明会的人员有：董事长赵叶青先生，总裁李家全先生， 财务总监孙瑞梅女士，董事会秘书 ...

Financial Performance - The company reported a non-operating income of 9,187,941.35 in 2022, a decrease from 12,720,543.88 in 2021[4]. - In 2022, the company achieved a revenue of 3.506 billion yuan, representing a year-on-year growth of 11.70%[39]. - The net profit attributable to shareholders reached 273 million yuan, a significant increase of 153.15%, with basic earnings per share of 0.71 yuan[39]. - The company's total equity attributable to shareholders at the end of the period was 3.607 billion yuan, up 6.27% year-on-year[39]. - The total operating revenue for the year 2022 reached ¥3,505,716,962.18, representing an increase of 11.70% compared to ¥3,138,454,280.12 in 2021[53]. - The revenue from the cephalosporin side-chain active ester series products was ¥842,208,709.22, accounting for 24.02% of total revenue, with a year-on-year growth of 21.29%[55]. - The company achieved a gross profit margin of 46.22% in 2022, which is a decrease of 6.40% from the previous year[55]. - Domestic sales contributed ¥2,759,545,004.79, representing 78.72% of total revenue, with a year-on-year increase of 13.58%[55]. - The contract research and production services segment saw a remarkable growth of 339.31%, with revenue reaching ¥231,058,425.65[55]. Research and Development - The company has maintained R&D investment at over 7% annually, employing 525 R&D personnel, including 135 with master's degrees or higher[28]. - The company has established a three-tier R&D innovation system, collaborating with universities to enhance its technological capabilities[28]. - The company has several ongoing R&D projects, including the development of new products such as sodium choline injection and the consistency evaluation of cefuroxime axetil capsules, which are expected to enhance market competitiveness[76]. - The establishment of a unified R&D platform and partnerships with academic institutions have accelerated innovation in synthetic biology[46]. - The capitalized R&D expenditure was ¥111,346,445.83, accounting for 44.16% of total R&D investment in 2022[79]. - R&D investment amounted to ¥252,126,641.05 in 2022, representing 7.19% of operating revenue, a decrease from 8.01% in 2021[79]. Market Expansion and Product Development - The company is actively expanding its market presence and product offerings in response to evolving healthcare needs and regulatory changes[9]. - The company is focusing on a "vertical integration" development strategy, enhancing its capabilities from fine chemicals to specialty APIs and terminal formulations[39]. - The company completed 10 new product registrations and achieved 3 domestic and 3 international approvals for APIs during the reporting period[46]. - The company is actively pursuing market expansion through new product development and international certifications[44]. - The formulation segment is expected to maintain strong momentum by cultivating key products and increasing market coverage and terminal growth[124]. Production and Operations - The company operates under strict GMP standards across its production subsidiaries, ensuring quality and compliance in manufacturing[16]. - The company has developed multiple drug formulation production lines, including injectables and various oral dosage forms[15]. - The company operates nine production bases across multiple provinces, focusing on cephalosporin intermediates and various dosage forms, with a leading market share in glutathione raw materials[29]. - The company has established two chemical raw material production platforms to enhance its product range and market competitiveness[15]. - The company has a production capacity ranging from milligram to ton levels, with a maximum total reaction volume of 5000 cubic meters for both chemical synthesis and biological fermentation[33]. Financial Management and Investments - The company has implemented significant investments in environmental safety and automation to enhance production efficiency and safety[40]. - The total investment during the reporting period was 89,640,000.00 CNY, representing a 59.05% increase compared to 56,360,000.00 CNY in the same period last year[91]. - The company is committed to ensuring that the total amount of raised funds remains unchanged despite adjustments in the internal investment structure due to rising costs and safety requirements[115]. - The company has established a management system for forward foreign exchange transactions to mitigate risks associated with currency fluctuations[103]. Risk Management - The company faces risks from industry policies, including price reductions and procurement policies, which could impact its R&D, production, and sales[133]. - The company acknowledges the high investment and long cycle risks associated with drug R&D, which may lead to project interruptions or market changes[134]. - The company is exposed to risks from raw material supply and price fluctuations, which could impact profitability; it aims to enhance supply chain management[136]. - The company is aware of risks related to export tax rebate rates and exchange rate fluctuations, and it plans to use hedging tools to manage these risks[140]. Corporate Governance and Compliance - The company emphasizes strict compliance with laws and regulations in its operations and governance[179]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring accountability and alignment with corporate goals[153]. - The company has a complete and independent financial institution, with independent accounting and financial management systems[164]. - The company has clear ownership of intellectual property rights, including patents and real estate[163]. Employee Development and Management - The company has established a comprehensive training system focusing on key positions and core personnel to enhance employee skills and adaptability to business needs[192]. - The company has implemented a "Starfire Plan" to select high-potential talents from recent graduates for grassroots talent reserves, aiming to build a talent pipeline[192]. - The company has a structured approach to employee development, including the "Torch Plan" for nurturing management-level talents from recent graduates[192].

Group 1: Market Demand and Product Advantages - The domestic market for glutathione raw materials is primarily driven by formulations, with major domestic manufacturers now relying on local suppliers instead of imports [2][3] - The company has advantages over Japanese imports due to guaranteed product quality and technological upgrades [3][4] - The main barriers to glutathione products are fermentation and purification stages, particularly in strain cultivation [3] Group 2: Export Markets and Sales Proportions - The company exports to North America, Southeast Asia, and Europe, with products already present in over ten countries including the USA, Italy, Germany, and Brazil [3][4] - The sales ratio of glutathione products is approximately 60% domestic and 40% international [4][5] Group 3: Strategic Developments - The acquisition of Tianchen Pharmaceutical is aimed at adapting to the company's strategic transformation and extending its operations into downstream industries [5] - The company is conducting market research and planning for the sales of its newly approved "Yikang Peptide" product while maintaining communication with health product enterprises [4][5]

Company Overview - Shandong Jincheng Pharmaceutical Co., Ltd. has been actively pursuing a comprehensive development strategy in the pharmaceutical and healthcare sectors since its IPO, focusing on internal growth, external expansion, and mergers and acquisitions [3][4]. Business Development - The company has successfully completed the acquisition of Shanghai Tianchen Pharmaceutical in 2014 and is planning significant asset restructuring to invest in Beijing Langyi Pharmaceutical in 2015, along with additional investments in Guangzhou Jincheng Daobofa Pharmaceutical [3][4]. - As of now, the company has established a complete industrial chain from intermediates and raw materials to finished formulations, forming three major business systems: antibiotics, biopharmaceuticals, and gynecological and immune-regulating preparations [3][4]. Financial Performance - The company reported a significant growth of over 60% in the first three quarters of the year, primarily driven by the robust performance of the antibiotics segment, which contributes approximately two-thirds of the overall revenue [4][5]. - Domestic and foreign trade revenues are roughly equal, each accounting for about half of the total revenue [4][5]. Product Development - The intermediates business has shown steady growth, with major product sales increasing and prices rising compared to the same period last year, attributed to the company's leading market position and continuous innovation [4][5]. - The biopharmaceutical product glutathione has established business collaborations with major domestic formulation manufacturers and is exported to Europe, America, and Southeast Asia, despite facing some revenue pressure due to price adjustments [4][5]. Future Plans - The company is focused on enhancing its terminal formulation sales channels and has initiated the construction of a sales platform, with core sales personnel already in place [5][6]. - Following the acquisition of Beijing Langyi Pharmaceutical, the company aims to expand its product offerings in antibiotics, biopharmaceuticals, and gynecological and immune-regulating sectors, while also exploring strategic investments in liver disease treatment and other health sectors [6].

Group 1: Company Overview - Jincheng Pharmaceutical has a diverse product range, including approved chemical drugs such as Nitrofurantoin Vaginal Gel Capsules and Pidotimod Dispersible Tablets, which have significant market potential [2] - The company possesses self-supply capabilities for raw materials, ensuring good quality assurance for its products [2] - Jincheng employs a combined marketing model of distribution and direct sales, supported by academic promotion and brand marketing strategies [2] Group 2: Key Products - The main products of Jincheng Pharmaceutical focus on gynecological and immune-regulating medications, with Nitrofurantoin Vaginal Gel Capsules being a leading product in the domestic market, holding the top market share across 34 provinces [3] - Pidotimod Dispersible Tablets, aimed at immune regulation, also lead the market among four main manufacturers [3] Group 3: Business Operations - The pricing and market demand for cephalosporin antibiotics remain stable [3] - Recent share reductions by company executives were attributed to personal financial needs rather than a lack of confidence in the company, with management expressing optimism about future development [3] Group 4: Future Development - Jincheng Pharmaceutical plans to utilize various development strategies, including potential acquisitions of companies that align with its growth direction and industrial goals [4]

Group 1: Sales and Market Strategy - The company plans to continue using the existing sales model for Langyi, leveraging its brand and channel management advantages, with no significant competitors currently in the market [2][3] - Langyi's sales budget and targets for 2015 have been communicated to sales personnel, ensuring accountability [3] - The company is actively working on integrating Langyi's products into local medical insurance systems, with tender processes expected to resume after June due to policy changes [3] Group 2: Production and Development - The construction of Langyi's facilities is progressing as planned, with the formulation workshop nearing completion and raw material workshops still under construction, primarily funded through self-raised capital [3][4] - The acquisition of Langyi is expected to enhance the company's raw material production capabilities and quality control, thereby improving product quality and reducing production costs [3][4] Group 3: Product Portfolio and Market Position - Langyi's main products, such as Nitrofurantoin and Pidotimod, are positioned well in the market, with Nitrofurantoin being the only dual-category product (prescription + OTC) and holding the highest market share in 34 provinces [4] - Pidotimod is a leading immune regulator with a significant market share, and the company anticipates substantial revenue growth from this product over the next five years [4][5] Group 4: Future Opportunities and Challenges - The company is cautious about entering the health supplement market due to stringent approval processes but will consider products with competitive advantages [5] - There are no current plans to enter the medical device and service sectors [5] - The market for glutathione is expected to grow due to its wide range of applications, with potential demand increases in agriculture, health supplements, and food sectors [5]